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Abstract
Background: Non-invasive delivery of nebulized surfactant has been a neonatology long-pursued goal.
Nevertheless, the clinical efficacy of nebulized surfactant remains inconclusive, in part, due to the great technical
challenges of depositing nebulized drugs in the lungs of preterm infants. The aim of this study was to investigate
the feasibility of delivering nebulized surfactant (poractant alfa) in vitro and in vivo with an adapted, neonate-
tailored aerosol delivery strategy.
Methods: Particle size distribution of undiluted poractant alfa aerosols generated by a customized eFlow-Neos
nebulizer system was determined by laser diffraction. The theoretical nebulized surfactant lung dose was estimated
in vitro in a clinical setting replica including a neonatal continuous positive airway pressure (CPAP) circuit, a cast of
the upper airways of a preterm neonate, and a breath simulator programmed with the tidal breathing pattern of an
infant with mild respiratory distress syndrome (RDS). A dose-response study with nebulized surfactant covering the
100–600 mg/kg nominal dose-range was conducted in RDS-modelling, lung-lavaged spontaneously-breathing
rabbits managed with nasal CPAP. The effects of nebulized poractant alfa on arterial gas exchange and lung
mechanics were assessed. Exogenous alveolar disaturated-phosphatidylcholine (DSPC) in the lungs was measured
as a proxy of surfactant deposition efficacy.
Results: Laser diffraction studies demonstrated suitable aerosol characteristics for inhalation (mass median
diameter, MMD = 3 μm). The mean surfactant lung dose determined in vitro was 13.7% ± 4.0 of the 200 mg/kg
nominal dose. Nebulized surfactant delivered to spontaneously-breathing rabbits during nasal CPAP significantly
improved arterial oxygenation compared to animals receiving CPAP only. Particularly, the groups of animals treated
with 200 mg/kg and 400 mg/kg of nebulized poractant alfa achieved an equivalent pulmonary response in terms of
oxygenation and lung mechanics as the group of animals treated with instilled surfactant (200 mg/kg).
Conclusions: The customized eFlow-Neos vibrating-membrane nebulizer system efficiently generated respirable
aerosols of undiluted poractant alfa. Nebulized surfactant delivered at doses of 200 mg/kg and 400 mg/kg elicited a
pulmonary response equivalent to that observed after treatment with an intratracheal surfactant bolus of 200mg/kg.
This bench-characterized nebulized surfactant delivery strategy is now under evaluation in Phase II clinical trial
(EUDRACT No.:2016–004547-36).
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Background
Current trends in the management of preterm infants
with Respiratory Distress Syndrome (RDS) aim for
gentler, non-invasive interventions as first-line treatment
options. Over the last years, the classic ways of providing
artificial respiratory support, oxygen therapy, and ex-
ogenous surfactant have been systematically challenged
[1–5] in order to reduce the iatrogenic effects that con-
tribute to the development of chronic lung disease [6, 7].
Particularly, clinical research has been directed to reduce
the use of mechanical ventilation [8–10], a major risk
factor associated with lung inflammation and the devel-
opment of Broncho-Pulmonary Dysplasia (BPD). There-
fore, non-invasive ventilation techniques are gaining
momentum as the primary treatment of RDS [10–13].
Surfactant replacement therapy has also undergone a
clear evolution towards less invasive administration
protocols [14]. Aerosol delivery of exogenous surfactant
in combination with nCPAP has been proposed as a
feasible, truly non-invasive surfactant delivery method
[15, 16]. The theoretical advantages of nebulization in-
clude minimal manipulation of the respiratory tract, im-
proved pulmonary distribution [17], and the avoidance
of the acute airway fluid load occurring immediately
after surfactant instillation [16]. A gradual surfactant
administration by nebulization may reduce some of the
side effects associated with surfactant instillation, e.g.
transient airway obstructions and reflux, hypercarbia,
and hypoxia [16], and may therefore contribute to more
stable systemic and cerebral hemodynamics [18–20]. Ex-
perimental studies with aerosolized surfactant, however,
have shown controversial results, ranging from no effect
at all of the aerosolized surfactant to an equivalent per-
formance compared to intratracheal bolus instillation
[17–30]. A few clinical studies have also attempted to
deliver nebulized surfactant to preterm infants managed
with CPAP [31–35]. These studies enrolled a limited
number of patients, applied heterogeneous surfactant
administration protocols, and used different nebulizers.
So far, these clinical studies have demonstrated that
nebulized surfactant is well tolerated and can be safely
administered during non-invasive ventilation.
A great challenge in the field of aerosol delivery is to
improve the extremely low lung deposition of inhaled
drugs in preterm neonates, which has been reported to
be lower than 1% of the nominal dose [36, 37]. Preterm
neonates are forced nasal breathers, have a low
functional residual capacity, high respiratory rate (RR),
low tidal volume, and small airway caliber [38]. All these
factors reduce the residence time of aerosol particles
within the airways, which significantly reduces lung de-
position. In addition, the bias flow of the ventilation sup-
port can dilute the concentration of surfactant droplets,
leading to a relatively high surfactant loss through the
expiratory limb of the CPAP circuit [38]. To overcome
these limitations, research efforts have been directed to
characterize, even further, the particular challenges
posed by preterm infants to aerosol delivery, as well as
to develop novel aerosol-generating devices and infant-
focused strategies aimed at improving lung deposition of
nebulized surfactant [39–45].
In the present work, we investigated the feasibility of
delivering nebulized surfactant in vitro and in vivo with
a customized, neonate-focused aerosol delivery strategy.
For that purpose, we first analyzed the aerosol character-
istics of nebulized poractant alfa (Curosurf®, Chiesi
Farmaceutici SpA, Parma, Italy) generated by a custom-
ized eFlow-Neos vibrating-membrane nebulizer system
(PARI Pharma, Starnberg, Germany) under physiological
relative humidity (RH) conditions. We further investi-
gated surfactant deposition in a realistic in vitro CPAP
circuit, which included a cast of the upper airways of a
preterm infant and a breath simulator programmed with
a neonatal breathing pattern. In vitro data were used to
implement surfactant nebulization in a nCPAP-
supported RDS animal model, in which a dose-response
study was performed to assess the pulmonary efficacy of
nebulized surfactant.
Materials and methods
Surfactant particle size characterization
The particle size distribution of surfactant aerosols
(poractant alfa, 80 mg/mL) generated by the customized
eFlow-Neos nebulizer system was determined in vitro by
laser diffraction (Helos/BF, Sympatec GmbH, Clausthal-
Zellerfeld, Germany). Briefly, this technique measures
the angular variation in the intensity of scattered light
when a laser is directed through a particle dispersion.
The angular variation in the intensity of scattered light
is inversely proportional to particle size, which allows
determining the size distribution of the particles in the
surfactant cloud. To perform laser diffraction experi-
ments, the customized eFlow-Neos was filled with 2 mL
of undiluted surfactant that was then continuously
nebulized towards the detection area. Laser diffraction
experiments were conducted at 30% ± 5 or, alternatively,
at 90% ± 5 relative humidity (RH) conditions, at 37 °C.
Each of these experiments was repeated five times using
independent nebulizer units. The mass median diameter
(MMD), the geometric standard deviation (GSD), and
the fine particle fraction (FPF) were used to characterize
surfactant aerosols.
Becnhmark breath simulation experiments
A set-up composed of a CPAP system (Fabian HFO,
Acutronic, Zug, Switzerland) with a humidifier (MR 730,
Fisher & Paykel Healthcare), a customized eFlow-Neos
nebulizer system, a cast of the upper airways (nose-
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throat) of a premature infant (PrINT model) [41], infant
nasal prongs (3520, Fisher & Paykel Healthcare), surfac-
tant collection filters (PARI Filter PAD PZN: 00632160),
and a breath simulator (Compas 2, PARI Pharma, Starn-
berg, Germany) [46, 47] was implemented in order to
simulate a clinical setting of surfactant nebulization
under non-invasive neonatal ventilation conditions. The
PrINT model was developed by Minocchieri et al. by 3D
reconstruction of a magnetic resonance of a premature
infant born after 32 weeks of gestation (body weight of
1750 g) [41]. The infant nose-throat cast was 3D printed
(1zu1 prototypen, Dornibirn, Austria) as a solid substance
(material: DSM water clear ultra 10,122). The nose area
was silicon-coated to achieve a tight connection between
cast and prongs (Additional file 1: Figure S1).
The nebulizer was placed between the Y piece and the
nasal prongs using a custom-made adaptor. Before sur-
factant nebulization, the set up was systematically
checked for air leaks. The temperature of the system
was 37 °C and the RH was set at 90% ± 5. Bias flow rate
and CPAP level were set at 5 L/min and 5 cmH2O,
respectively. The breath simulator was programmed with
the following neonatal configuration: RR of 70 bpm, a
tidal volume (VT) of 8.9 mL (5 mL/kg), and an inhal-
ation/exhalation ratio of 40/60.
A volume of 4.37 mL of poractant alfa (80 mg/mL),
the equivalent volume of a 200 mg/kg dose for a 1750 g
infant, was loaded into the customized nebulizer reser-
voir and was continuously nebulized. Surfactant collec-
tion filters were placed in the expiratory limb of the
CPAP system (exhalation filter) as well as at the distal
airway of the PrINT cast (Filter for lung dose, Fig. 1a).
Lung dose (LD) was defined as the amount of surfactant
collected within the filter placed at the distal airway of
the PrINT cast (In-Filter). A backup-trap was installed
between the PrINT cast and the In-Filter in order to col-
lect the surfactant liquid film formed from the already
impacted aerosol particles. The backup-trap did not have
a significant impact on the aerosol flow. The amounts of
surfactant deposited in the CPAP circuit, exhalation fil-
ter, backup-trap, nasal prongs, and residual surfactant
remaining in the nebulizer were also determined, after
dissembling of the analytical setup. After nebulization of
the full surfactant dose, the required nebulization time
was noted. A rinsing solvent containing 50mg of
potasium nitrate and 85% v/v isopropanol was used to
recover the surfactant from each compartment of the
analytical set up. Samples for quantitative analysis were
prepared by defined dilutions. The main active constitu-
ent of poractant alfa, i.e. Phosphatidylcholine (PC), was
determined as lead compound in order to quantify the
surfactant amount. A validated high-pressure liquid
chromatography (HPLC) method using external stand-
ard calibration was used for quantifying PC distribution
in the set-up compartments. The method is sensitive
enough to determine PC in the applied concentration
range from 20 to 2100 μg/ml for poractant alfa if a dual
wavelength detector (WATERS 2487, Waters Corpor-
ation, Milford, US) is used.
Animal preparation
The experiments were carried out in 6- to 7-week-old
male rabbits (Charles River Laboratories, Calco, Italy).
The experimental procedure was approved by the intra-
mural Animal Welfare Body and the Italian Ministry of
Health (Prot.n° 1300–2015-PR) and complied with the
European and Italian regulations for animal care.
Rabbits (body weight of 1.5–2.5 kg) were initially
sedated with intramuscular (i.m.) medetomidine
(Domitor®, 2 mg/kg). The throat of the animals was
first shaved and local anesthesia was applied in the
anterior neck with lidocaine gel (Luan® 2.5%). Thirty
minutes later, the animals received 50mg/kg of ketamine
(Imalgene 1000®, Merial-Boehringer Ingelheim, France)
and 5mg/kg of xylazine (Rompun®, Bayer, Germany) i.m.
Rabbits, in the supine position, were intubated and stabi-
lized on positive pressure ventilation (Fabian HFO, Acu-
tronic, Zug, Switzerland) as previously described [48, 49].
Fraction of inspired oxygen (FiO2) = 100%, Flow = 10 L/
min, RR = 40 breaths/min, positive end-expiratory pres-
sure (PEEP) = 3 cmH2O, tidal volume (VT) targeted to 7
ml/kg (with the peak inspiratory pressure, PIP, not exceed-
ing 15 cmH2O) and inspiratory time of 0.5 s. Airway flow,
mean airway pressure (MAP) and VT were monitored as
long as the animals were intubated. Body temperature was
constantly measured with a rectal probe and maintained
at 37 degrees by placing a heating pad underneath the
animal.
After endotracheal intubation, a catheter was inserted
into the right jugular vein for continuous infusion of 1
mg/ml of ketamine and 0.1 mg/ml of xylazine in 0.9% sa-
line solution (100 μl/min) to maintaining anesthesia at a
steady level. Trometamol (tris-hydroxymethyl amino-
methane, THAM, 1M, Sigma-Aldrich, USA) was also in-
fused during the surfactant depletion procedure for
mantaing CO2 level under control. A second catheter
was inserted into the right carotid artery for blood sam-
pling. After instrumentation, baseline blood gases were
measured with an emogas analyzer (Radiometer Medical,
Denmark).
Animals with an initial arterial oxygen partial pres-
sure (PaO2) value > 400 mmHg at PIP < 15 cmH2O
were included in the study. Repeated broncho-alveolar
lavages (BALs) were performed by flushing the
airways with 20 ml/kg of pre-warmed 0.9% NaCl solu-
tion, followed by a short recovery period in-between,
until a PaO2 value < 150 mmHg was reached. Then, if
after 15 min of stabilization on mechanical ventilation
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the respiratory failure was confirmed (PaO2 < 150
mmHg, with PIP not exceeding 23 cmH2O), the
animal was included in the study.
Experimental groups
Forty-two animals were allocated to one of the six ex-
perimental groups. Animals in the nCPAP group (n = 6)
were maintained in continuous nCPAP (Fabian HFO,
Acutronic; 5 cmH2O) for 180 min, using customized
nasal prongs as an interface. Animals allocated in the
Inst-SURF group (n = 9) received an intratracheal bolus
of poractant alfa (200 mg/kg), using a modified
InSurE approach, and were further managed with
nCPAP (5 cmH2O) for 180 min. After surfactant in-
stillation, animals were managed with mechanical
ventilation for 10 min (VT = 7 mL/Kg, RR = 40/min
and PEEP = 3 cmH2O). Animals receiving nebulized
surfactant were allocated in four different groups of
escalating surfactant doses. The customized eFlow-
Neos nebulizer was placed between the Y piece and
the customized nasal prongs. Rabbits in the Neb-
SURF100 group (n = 9) received 100 mg/kg of nebu-
lized poractant alfa while on nCPAP, whereas animals
in the Neb-SURF200 (n = 9), Neb-SURF400 group
(n = 9), and Neb-SURF600 group (n = 9) received
200 mg/kg, 400 mg/kg, and 600 mg/kg of nebulized
poractant alfa, respectively. All animals treated with
nebulized surfactant were managed with nCPAP (5
cmH2O) for 180 min, counting from the initiation of
surfactant nebulization. For each animal experiment, a
new customized eFlow-Neos nebulizer unit was used.
The time required to nebulize the whole surfactant
dose was annotated.
Gas exchange and respiratory indices
Arterial carbon dioxide partial pressure (PaCO2), PaO2,
and pH were measured (Radiometer Medical, Denmark)
right after the induction of anesthesia (baseline) and
after the induction of respiratory distress. Arterial blood
gases were also measured right after placing the animals
on nCPAP, 15 and 30min after the start of nCPAP, and
then every 30 min until the end of the experiment.
Fig. 1 (a) Scheme of the experimental setup. (b) Mass median diameter (MMD) of nebulized surfactant measured by laser diffraction under
different relative humidity (RH) conditions. (c) Fine particle fraction (FPF) of nebulized surfactant under different RH conditions. (d) Mean
cumulative percentage of deposited surfactant within the different setup compartments (n = 5) and cumulative percentage of deposited
surfactant for individual experiments, each of them conducted with independent nebulizer units. * P vs. RH 30% < 0.01
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PaO2 and PaCO2 were also used to compute the
oxygenation index (OI) and the ventilation efficacy index
(VEI). OI and VEI were determined at those time inter-
vals in which the animals were ventilated with a tracheal
tube: at baseline, after inducing the respiratory distress
and at the end of the 180 min follow-up period. There-
fore, after the 180 min observational period, animals
were shifted from nCPAP to invasive mechanical ventila-
tion for a brief period of time, using exactly the same
ventilation settings as at baseline (FiO2 100%, Flow = 10
L/min; RR = 40 bpm, PEEP = 3 cmH2O, VT targeted to 7
ml/kg, and inspiratory time of 0.5 s). The OI was calcu-
lated as follows:
OI ¼ FiO2 MAP  100=PaO2 ð1Þ
The VEI was calculated to evaluate the overall
ventilation efficiency of mechanically ventilated animals
independently from the ventilation settings [50]:
VEI ¼ 3800= PIP=PEEPð Þ  RR  PaCO2½  ð2Þ
Ventilation indices were calculated at baseline (pre-
BALs), after inducing respiratory distress (post-BALs),
and at the end of the observational period.
Pulmonary mechanics
Dynamic compliance (Cdyn) was also determined in
those time intervals in which the animals were ventilated
with invasive mechanical ventilation: at baseline, resem-
bling the “healthy” pulmonary status, right after inducing
severe respiratory distress by repeated BALs, and at the
end of the observational period, after re-intubation. Cdyn
was calculated by dividing lung volume (ΔV, in mL) by
the changes in pressure (ΔP) standardized by the
animal’s weight.
Cdyn ¼ ΔV= ΔP Weightð Þ ð3Þ
Exogenous alveolar disaturated-phosphatidylcholine
(DSPC) quantification
Intrapulmonary levels of exogenous surfactant were
determined by administering poractant alfa labelled with
U13C-PA-DPPC (n = 3 animals for each group). For
tracer preparation, 0.2 mg (0.1 μl) of a suspension of
U13C-PA-DPPC (Avanti Polar Lipids) in saline solution
was carefully mixed with 200 mg (2.5 ml) of poractant
alfa, which was then administered to distressed rabbits
as described in the previous section. At the end of the
experiment, BALs from all animal groups were collected
and stored at − 80 °C. Lipids were extracted according to
the method described by Bligh and Dyer [51].
Disaturated-phosphatidylcholine (DSPC) was separated
by thin layer chromatography after treatment with
osmium tretaoxide [52]. Fatty acids of DSPC were deri-
vatized as methyl ester by adding 2 mL 3M HCl metha-
nol and extracted with hexane. Quantitative analysis of
DSPC was performed by a FID gas chromatograph (GC,
Agilent 5890, Milan, Italy). The 13C enrichment of DSPC
from the BALs was measured with gas chromatography-
mass spectrometry (GC-MS, Agilent, 5973 Inert), as de-
scribed elsewhere [53]. For data display, the intrapul-
monary exogenous surfactant amount of the animals
treated with nebulized surfactant was normalized taking
the surfactant instillation group as reference.
Data analysis
In vitro and in vivo data are presented as mean ± SD.
Raw data were analyzed and compared by repeated
measures two-way analysis of variance (ANOVA) as a
function of group and time, followed by Dunnett’s and
Tukey’s t posthoc tests. Statistical analysis was per-
formed using GraphPad software, version 6.0. A P < 0.05
was considered statistically significant.
Results
Particle size characterization of nebulized surfactant
Under low RH conditions (30% ± 5), the mean MMD of
nebulized surfactant was 2.6 ± 0.1 μm. Increasing RH
close to lung physiological conditions (90% ± 5)
produced a slight, although significant, increase of the
mean MMD to 3.0 ± 0.1 μm (Fig. 1b). Irrespective of RH
conditions, all tested customized eFlow-Neos nebulizers
showed a reproducible performance in terms of particle
size with a consistent GSD of 1.5, indicative of a hetero-
disperse aerosol yet with a narrow variability in terms of
particle size distribution.
The slight increase of the MMD under high RH
conditions was associated with a slight decrease of the
FPF. This parameter represents the percentage of parti-
cles contained in the aerosol cloud with a diameter
below 5 μm, also known as the respirable fraction. Mean
FPF values determined under low and high humidity
conditions were 97.2% ± 0.4 and 93.7% ± 1.1, respectively
(Fig. 1c).
Benchmark breath simulation experiments
The mean nebulization time to deliver 4.37 mL of sur-
factant (80 mg/mL) was 18.9 min (range 13.3–23.3 min),
which corresponds to an aerosol production rate of 18.5
mg phospholipid/min (range 15.0–26.3 mg/min). The
determined mean LD was 13.7% ± 4.0 (range 10.2–
19.8%, Fig. 1d and e), which would yield an estimated
intrapulmonary surfactant dose of around 27mg/kg in
vivo if a 200 mg/kg dose was delivered. A fraction of
generated aerosol was deposited on the backup-trap
(36.7% ± 5.3), whereas 20.3% ± 1.5 was detected in the
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exhalation filter of the CPAP circuit. Only 3.0% ± 0.6 of
the nebulized surfactant deposited within the PrINT cast
and 7.2% ± 2.1 was collected as a residual volume in the
nebulizer chamber. Surfactant recovery was 81.0% ± 6.9.
The undetected surfactant fraction may have remained
within the circuit as non-deposited particles that were
further released to the environment during set up
disassembling.
Gas exchange and respiratory indices
There were no significant differences between groups at
baseline in terms of body weight, number of BALs
needed to achieve the targeted respiratory failure, PaO2
or Cdyn (Additional file 1: Table S1). All animals had
similar mean PaO2 at baseline (> 450 mmHg). However,
following surfactant-depletion, a severe respiratory fail-
ure developed in all groups (mean PaO2 < 150 mmHg).
The PaO2 in the nCPAP group remained extremely low,
below 100mmHg, despite a FiO2 of 100%. PaO2 values
rapidly increased right after surfactant instillation,
reaching mean PaO2 values above 200 mmHg 15 min
after treatment (Fig. 2a). PaO2 values remained sig-
nificantly higher throughout the whole experimental
period in the Inst-SURF group compared to the
nCPAP group (P < 0.01). In the groups of animals
treated with nebulized surfactant, PaO2 increased
gradually over time achieving significantly higher values
compared to untreated control animals (P < 0.01). How-
ever, whereas mean PaO2 values of Neb-SURF200 and
Neb-SURF400 groups were equivalent to the mean PaO2
of the Inst-SURF group at 180min, the mean PaO2 of the
Neb-SURF100 group was significantly lower (P < 0.01)
compared to the latter group. The Neb-SURF600 group
showed slightly lower mean PaO2 values than Neb-
SURF200 and Neb-SURF400 groups at 180min.
Surfactant depletion by BALs was associated with se-
vere hypercapnia and acidosis in all groups. Hypercapnia
exacerbated even further in the nCPAP group, whereas
surfactant-treated groups showed a downward trend of
mean PaCO2 values (Fig. 2b). However, a significant
reduction of PaCO2 in comparison to the nCPAP group
was only observed for Inst-SURF, Neb-SURF200 and
Neb-SURF400 groups (P < 0.05). Severe acidosis (pH < 7.2)
persisted in the nCPAP group for the whole 180min fol-
low up period, with pH values that were significantly
lower compared to any surfactant-treated group (Fig. 2c).
At baseline, OI was below 1.5 and the VEI above 0.15 in
all study subjects. After BALs, mean OI increased to
10.84 ± 2.94 and the VEI dropped to 0.06 ± 0.01 (Fig. 3).
At the end of the experimental period, OI was significantly
lower in all surfactant-treated groups compared with the
nCPAP group (P < 0.01). At 180min, VEI remained low in
the nCPAP group but increased in all surfactant-treated
groups. However, a significant improvement of VEI
compared to the nCPAP group was only observed for
Inst-SURF and Neb-SURF400 groups (P < 0.05).
Pulmonary mechanics
Cdyn significantly dropped in all groups after the induc-
tion of respiratory failure (Fig. 4). Mean Cdyn values
measured after 180min were relatively low in nCPAP
(0.38 ± 0.06 mL/cmH2O/kg) and Neb-SURF100 (0.46 ±
0.05 mL/cmH2O/kg) groups. Conversely, mean Cdyn
values significantly increased in the Inst-SURF, Neb-
SURF200 and Neb-SURF400 groups after 180 min of
non-invasive ventilation compared to the nCPAP group
(P < 0.05).
Alveolar DSPC quantification
The mean amount of exogenous DSPC in the Neb-
SURF100 was 33-fold lower compared to the Inst-SURF
group. Conversely, the Neb-SURF200 group registered
an amount of exogenous DSPC 3.7-fold lower compared
to the Inst-SURF group. Neb-SURF400 and Neb-
SURF600 groups showed the highest mean intrapulmon-
ary DSPC amounts just 1.8- and 1.2-fold lower com-
pared to the animals which received intratracheal
surfactant. These groups, however, showed a high inter-
animal variability (Additional file 1: Figure S2).
Discussion
We investigated the feasibility of delivering undiluted
nebulized surfactant with the customized eFlow Neos
vibrating-membrane nebulizer system under realistic
neonatal ventilation conditions. Laser diffraction studies
demonstrated suitable aerosol characteristics for inhal-
ation in terms of particle size distribution and fine par-
ticle fraction. The theoretical surfactant LD determined
in vitro in a rational neonatal CPAP circuit, which in-
cluded the simulated breathing pattern of a preterm in-
fant with mild RDS, reached notable values for neonatal
standards, as high as 19.8% of the nominal dose. Further,
a dose-response study conducted in spontaneously-
breathing lung-lavaged rabbits revealed a significant im-
provement of arterial oxygenation following treatment
with nebulized surfactant. Particularly, the groups of ani-
mals treated with 200 mg/kg and 400mg/kg of nebulized
poractant alfa achieved an equivalent pulmonary
response as the group of animals treated with instilled
surfactant (200 mg/kg).
The concept of nebulized surfactant dates back to
1964 and was indeed one of the first attempts to treat
preterm infants with RDS [54, 55]. Nevertheless, aerosol
technology and lung deposition mechanisms were
poorly understood at that time, which moved the field
to the development of intratracheal instillation proto-
cols [56, 57]. Since then, surfactant replacement ther-
apy has undergone a constant evolution towards a
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less invasive administration [4, 9, 58]. At present, the
LISA method is experiencing worldwide clinical ap-
praisal. This technique significantly reduces the need
for mechanical ventilation and oxygen supplementa-
tion, and may as well reduce the incidence of BPD
[59]. However, it still involves the acute fluid load of
the infant’s airway, which may lead to transient airway
obstruction, surfactant reflux, and hemodynamic im-
balance [16].
In this study, we intended to develop a neonate-
focused surfactant nebulization strategy, taking into
consideration not only the particular characteristics of
preterm infants but also the relatively high viscosity of
surfactant. Finner et al. reported marked variability in
surfactant dose output among single Aeroneb Pro
(Aerogen) vibrating-membrane nebulizer units during a
pilot clinical study evaluating the potential of aerosolized
surfactant for the prevention of RDS [34]. The authors
attributed the variability in dose output to higher viscos-
ity of surfactant compared to medications which are
routinely delivered as aerosols. They discouraged the use
of this device in combination with surfactant. Additional
studies with nebulized surfactants have reported clog-
ging of the pores of the vibrating membrane of the
nebulizer, requiring surfactant dilution before nebuliza-
tion [30, 60]. In the present study, the customized
eFlow-Neos nebulizer system was able to produce respir-
able aerosols of poractant alfa, a highly concentrated
surfactant, which is formulated at around 80 mg of phos-
pholipids/mL. It is noteworthy that particle size distribu-
tion, as well as the output rate of the single customized
eFlow-Neos nebulizing units, showed consistent results.
We used new nebulizer units for each in vivo experi-
ment, as well as 5 independent units for the in vitro
Fig. 2 Mean PaO2 (a), PaCO2 (b), and pH (c) values over time in surfactant-depleted adult rabbits treated with nasal continuous positive pressure
ventilation (nCPAP, black squares), with intratracheal surfactant (Inst-SURF, white squares), or with different doses of nebulized surfactant (Neb-
SURF100, up-pointing triangles; Neb-SURF200, down-pointing triangles; Neb-SURF400, right-pointing triangles; and Neb-SURF600, left-pointing
triangles). Values are shown as the mean ± SD. * P vs. nCPAP < 0.01; # P vs. Inst-SURF < 0.05
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study, overall analyzing the performance of 41 nebulizer
units. All units showed a consistent output rate and
performed well with undiluted poractant alfa
(Additional file 1: Figure S3).
We further tested the customized eFlow-Neos
nebulizer in a rational neonatal CPAP circuit. In order
to maximize the surfactant LD, we placed the nebulizer
between the Y piece and the nasal prongs. Surfactant
aerosols were thus generated close to the nares of the
PrINT model. This cast resembles the upper airways
(nose-throat) of a premature infant born at a gestational
age of 32 weeks and is a useful tool to estimate the LD
of nebulized medications intended for delivery to
preterm infants [41]. Minocchieri et al. investigated the
theoretical LD of inhaled budesonide generated with an-
other vibrating-membrane nebulizer prototype (e-Flow,
PARI GmbH Starnberg, Germany). They found that the
LD dropped from around 62 to 9% of the nominal dose
if the bias flow-rate was increased from 1 L/min to 10 L/
min [41]. In comparison to their set up, we used humidi-
fied air, a bias flow of 5 L/min, a CPAP support of 5
cmH2O, and simulated the breathing pattern of a neo-
nate with mild RDS. Under such a challenging configur-
ation, the minimal and maximal surfactant LDs were
10.2 and 19.8% of the nominal dose (200 mg/kg),
respectively, corresponding to surfactant doses of 20.4
mg/kg and 39.6 mg/kg. Since individual nebulizer units
showed a consistent performance in terms of surfactant
output and particle size, we assume that the variability
Fig. 3 Box-plots showing (a) the oxygenation index (OI) and (b) ventilation efficacy index (VEI) at baseline (from all animals), after inducing a
respiratory distress (Post BALs, from all animals) and 180min after treatment with just nasal continuous positive pressure ventilation (nCPAP), with
different doses of nebulized surfactant (Neb-SURF100, Neb-SURF200, Neb-SURF400, Neb-SURF600) or with intratracheal surfactant (Inst-SURF). The
boxes encompass the 25–75 percentiles. The horizontal line within the boxes represents the median. The whiskers indicate the maximum and
minimum values observed for each group. * P vs. nCPA P < 0.01; # P vs. Inst-SURF < 0.05
Fig. 4 Box-plots showing dynamic compliance (Cdyn) at baseline
(from all animals), after inducing a respiratory distress (Post BALs,
from all animals) and 180min after treatment with just nasal
continuous positive pressure ventilation (nCPAP), with different
doses of nebulized surfactant (Neb-SURF100, Neb-SURF200, Neb-
SURF400, and Neb-SURF600) or with intratracheal surfactant (Inst-
SURF). The boxes encompass the 25–75 percentiles. The horizontal
line within the boxes represents the median. The whiskers indicate
the maximum and minimum values observed for each group. The
whiskers indicate the maximum and minimum values observed for
each group. * P vs. nCPAP < 0.05
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in LD observed for each single experiment may be rather
related to slight changes in the positioning of the com-
ponents of the circuit (e.g. small changes in the angle
of the prongs) or to slight variations of the air-flow
of the circuit from experiment to experiment.
Nevertheless, considering that intrapulmonary doses
as low as 2 mg/kg of nebulized surfactant have been
associated with a significant improvement of lung
mechanics [22], we performed a dose-response study
using four escalating nominal doses of poractant alfa
(dose-range 100–600 mg/kg).
The in vivo study was conducted in lung-lavaged,
spontaneously-breathing rabbits managed with nCPAP
[48]. A particular advantage of this model is that the
animals do not spontaneously recover from the
respiratory distress if they are just supported with
non-invasive ventilation [48, 49]. Therefore, any
improvement of oxygenation or lung mechanics
observed over time can be attributed to lung depos-
ition of active exogenous surfactant. A surfactant dose
of 100 mg/kg produced already a significant improve-
ment of arterial oxygenation. According to our in
vitro study, a nominal dose of 100 mg/kg would
achieve a LD of 13.7 mg/kg. Nevertheless, this dose
did not suffice to revert the respiratory distress. On
the other hand, nebulization of 200 and 400 mg/kg of
surfactant was associated with a significant improve-
ment of arterial oxygenation, respiratory indices, and
pulmonary mechanics, achieving a pulmonary
response at the same level of that observed for ani-
mals treated with an intratracheal bolus of 200 mg/kg
of surfactant. It is noteworthy that such an improve-
ment was achieved administering nebulized surfactant
to spontaneously-breathing animals managed with
nCPAP. These results are highly encouraging from a
clinical point of view.
As a proxy of surfactant lung deposition, we deter-
mined the amount of exogenous DSPC in three animals
of each surfactant-treated group. Although the limited
sample size precluded a sound statistical test, a clear
dose-dependent trend could be identified across the
groups of animals treated with nebulized surfactant.
Linner et al. determined by means of gamma scintig-
raphy that approximately 90% of the instilled surfactant
reaches the lungs following intratracheal admnistration
[60]. Therefore, we normalized the exogenous DSPC
amount of the groups of animals treated with nebulized
surfactant to the DSPC amount determined for the Inst-
SURF group. The relative exogenous DSPC quantified in
the BALs of Neb-SURF200 was almost 4.0-fold lower
compared to the BALs of the Inst-SURF group, even
though the elicited pulmonary response was equivalent
in both groups. We speculate that a more uniform intra-
pulmonary spreading of surfactant after nebulization
might have accounted for the similar pulmonary out-
come observed for both groups. Our data also suggest
that a nominal surfactant dose of 400mg/kg may be of
further advantage because it provides a good short term
pulmonary response but also contributes to increase the
intrapulmonary surfactant pool. Surprisingly, a further
increase of the nominal dose to 600 mg/kg did not
produce additional benefits in terms of gas exchange
or pulmonary mechanics. This was an unexpected re-
sult. In other animal models, high surfactant doses
have been associated with increased inflammation and
neutrophil migration [61] as well as with a reduction
of the antibacterial defenses [62]. Nevertheless, we
suspect that in this study the continuous nebulization
of 600 mg/kg of surfactant may have produced surfac-
tant accumulation in the airways, which would partly
explain lower PaO2 and slightly higher PaCO2 values
of this groups compared to Neb-SURF200 and Neb-
SURF400 groups. Unfortunately, we could not
determine the pulmonary distribution of nebulized
surfactant in this work and we acknowledge this as a
limitation of the study.
Conclusion
We have carried out a complete preclinical assessment
of the customized eFlow-Neos nebulizer operated with
poractant alfa for the treatment and prevention of RDS.
The nebulizer efficiently generated respirable aerosols
out of undiluted surfactant, yielding an estimated mean
lung deposition of 13.7% in vitro. Benchmark experi-
ments settled the basis to implement a dose-response
study in spontaneously-breathing rabbits with severe re-
spiratory distress. Nominal surfactant doses of 200mg/
kg and 400 mg/kg delivered with the customized eFlow
neos nebulizer during nCPAP significantly improved
oxygenation, respiratory indices, and lung compliance,
eliciting a pulmonary response equal to the one ob-
served for the group of animals treated with an intratra-
cheal bolus of 200 mg/kg of surfactant. The lung
improvement induced by surfactant nebulization was
achieved with a lower intrapulmonary surfactant dose
compared to the InSurE approach. The neonate-focused
surfactant nebulization strategy described in this work is
currently being evaluated in Phase II clinical trial
(EUDRACT No.:2016–004547-36).
Additional file
Additional file 1: Table S1. Baseline and post lung injury (Post-BAL)
characteristics of surfactant-depleted adult rabbits treated with nasal
continuous positive pressure ventilation (nCPAP), with intratracheal
surfactant (Inst-SURF), or with different doses of nebulized surfactant
(Neb-SURF100, Neb-SURF200, Neb-SURF400, and Neb-SURF600.
Figure S1. PrINT cast with silicon-coated nostrils. Figure S2. Nebulizer
output assessment. (DOCX 239 kb)
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